Galectin Therapeutics Inc. beat EPS estimates 33% of the time across 3 reported quarters (1 beats, 2 misses), averaging -23.0% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.09 | $-0.14 | -55.6% | Miss | |
| Q1 FY26 | $-0.06 | $-0.08 | -33.3% | Miss | |
| Q4 FY25 | $-0.10 | $-0.08 | +20.0% | Beat |
Back to GALT overview · GALT holders · GALT KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.